158 related articles for article (PubMed ID: 19099202)
1. Ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Thiel E; Bechrakis NE; Willerding G; Kraemer DF; Fischer L; Korfel A
J Neurooncol; 2009 Jun; 93(2):213-7. PubMed ID: 19099202
[TBL] [Abstract][Full Text] [Related]
2. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.
Jahnke K; Korfel A; Komm J; Bechrakis NE; Stein H; Thiel E; Coupland SE
Graefes Arch Clin Exp Ophthalmol; 2006 Jun; 244(6):663-9. PubMed ID: 16228920
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
[TBL] [Abstract][Full Text] [Related]
6. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
7. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.
Witte HM; Riecke A; Mayer T; Bartscht T; Rades D; Lehnert H; Merz H; Fetscher S; Biersack H; Gebauer N
J Cancer Res Clin Oncol; 2019 Jan; 145(1):129-136. PubMed ID: 30327940
[TBL] [Abstract][Full Text] [Related]
8. Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma.
Gunsilius E; Gierlich T; Mross K; Gastl G; Unger C
Cancer Invest; 2001; 19(8):808-11. PubMed ID: 11768034
[TBL] [Abstract][Full Text] [Related]
9. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
11. Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study.
Helsing MD
Eur J Cancer; 1997 Mar; 33(3):500-2. PubMed ID: 9155539
[TBL] [Abstract][Full Text] [Related]
12. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
Fischer L; Korfel A; Kiewe P; Neumann M; Jahnke K; Thiel E
Ann Hematol; 2009 Feb; 88(2):133-9. PubMed ID: 18679681
[TBL] [Abstract][Full Text] [Related]
13. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.
Reichardt P; Pink D; Tilgner J; Kretzschmar A; Thuss-Patience PC; Dörken B
Onkologie; 2002 Dec; 25(6):541-6. PubMed ID: 12566899
[TBL] [Abstract][Full Text] [Related]
14. The role of ifosfamide in the treatment of lymphomas.
Hagemeister FB
Leuk Lymphoma; 1999 Aug; 34(5-6):433-41. PubMed ID: 10492066
[TBL] [Abstract][Full Text] [Related]
15. Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature.
Jahnke K; Bechrakis NE; Coupland SE; Schmittel A; Foerster MH; Fischer L; Thiel E; Korfel A
Graefes Arch Clin Exp Ophthalmol; 2004 Sep; 242(9):771-6. PubMed ID: 15349786
[TBL] [Abstract][Full Text] [Related]
16. Trofosfamide in patients with pancreatic cancer.
Schmidt-Sandte W; Dageförde J; Klapdor R; Wagner T; Wiedemann GJ
Anticancer Res; 1999; 19(4A):2485-7. PubMed ID: 10470179
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma.
Kollmannsberger C; Brugger W; Hartmann JT; Maurer F; Böhm P; Kanz L; Bokemeyer C
Anticancer Drugs; 1999 Jun; 10(5):453-6. PubMed ID: 10477164
[TBL] [Abstract][Full Text] [Related]
18. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
20. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors.
Kiewe P; Thiel E; Reinwald M; Korfel A
J Neurooncol; 2011 Jul; 103(3):629-34. PubMed ID: 20941526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
